| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(8 months ago) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(a month from now) | |
Ozurdex is owned by Allergan.
Ozurdex contains Dexamethasone.
Ozurdex has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Ozurdex are:
- US10702539
- US8034366
- US8034370
- US8506987
- US9192511
- US10076526
Ozurdex was authorised for market use on 17 June, 2009.
Ozurdex is available in implant;intravitreal dosage forms.
Ozurdex can be used as delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex, treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye, treatment of macular edema; treatment of uveitis.
The generics of Ozurdex are possible to be released after 01 November, 2023.
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting t...
Dosage: IMPLANT;INTRAVITREAL
OZURDEX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic